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Indoor air pollution is composed of many
different agents that come from a variety of
sources. These include volatile organic com-
pounds from building materials, combus-
tion products such as environmental tobac-
co smoke (ETS), radon gas, molds, dusts,
fibers, etc. (1,2). Concentrations ofmany of
these substances in the indoor environment
exceed median outdoor air concentrations
byfactors of2-5 (3).
Several of these indoor exposures have
been implicated as possible or probable
human respiratory carcinogens. Chief
among these are radon and ETS (2). Radon
and its decay products have been character-
ized as the second leading contributor to
lung cancer and as the causeofup to 20,000
(or more) lung cancer deaths yearly in the
United States (4,5). This figure represents
an estimated 10% ofall lung cancers in the
United States (6). Lifetime exposure to the
average radon concentration in U.S. single-
family houses (40 Bq/m3) could result in an
excess lung cancer riskexceeding 1 in 1,000,
with higher exposure levels causing a risk in
excess of 1 in 100 [1 Bq/m3 is equal to
approximately 0.04 pCi/liter] (6).
Similarly, a growing body of evidence
implicates ETS as a possible cause oflung
cancer in humans (7-10). Environmental
tobacco smoke contains numerous carcino-
gens, including benzene, nitrosamines, and
benzo(a)pyrene (8,11). These carcinogens
are often in higher concentrations than in
mainstream smoke (11). Exposure to envi-
ronmental tobacco smoke is fairly com-
mon, with one study reporting that 63%
of the nonsmokers surveyed were exposed
to some level of ETS (8,12). It has been
estimated that 20-30% ofthe lung cancers
among nonsmokers in western countries
may be due to ETS (13).
Two avenues ofresearch, rodent bioas-
says and human observational epidemiolo-
gy, have traditionally been used to investi-
gate the carcinogenicity ofpollutants; how-
ever, both of these investigational tech-
niques have weaknesses that limit their util-
ity. Because of this, a weight-of-evidence
approach to carcinogenicity is usually used.
The strength of evidence from both the
human data and laboratory data are evaluat-
ed and used to classify an agent as a proven,
probable, or possible human carcinogen; a
noncarcinogen; or not classifiable (14).
To complement these approaches and
overcome some of their limitations, espe-
cially relating to the carcinogenicity of
indoor air pollution, we present a third
investigative approach: pet epidemiology.
This approach uses naturally occurring can-
cers in pet animals as surrogates of human
cancer risk. We will present the history of
pet epidemiology as it pertains to the study
of domestic carcinogens and discuss the
strengths and limitations of the approach.
Although this line ofresearch could investi-
gate cats, birds, and other household pets,
previous pet epidemiology has investigated
dogs almost exclusively. Therefore, we will
limit our discussion to dogs and focus on
the two main suspect indoor respiratory
carcinogens, ETS and radon.
Limitations of Rodent
Bioassays
Animal bioassays, as currently practiced, are
designed to screen qualitatively for the car-
cinogenicity of a chemical and to provide
data for potency slope estimation (15). In
these experiments, animals from both sexes
of two species (usually rats and mice) are
dosed repeatedly with the test agent, and a
similar number ofcontrol animals are either
not treated or treated with placebo. After 2
years (an average lifespan for rodents), both
the test and control animals are sacrificed
and examined for the presence of cancer in
anyoftheir organs.
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The test animals are typically assigned
to one to two dosage groups, one ofwhich
is the maximum tolerated dose (MTD).
The National Toxicology Program (NTP)
defines the MTD as "the highest dose of
the test agent during the chronic study that
can be predicted not to alter the animals'
longevity from effects other than carcino-
genicity" (16-18). This high dose is needed
to increase the power ofthe study to detect
an effect in a relatively small number of
animals. Ifa lower dosage group is used, it
is usually set at one-tenth to one-half the
MTD, which is still quite high compared
to realistic environmental exposure levels
(15). Indeed, bioassays typically do not
provide much information about the car-
cinogenicity of chemicals at doses much
lower than halfthe MTD (15).
The MTD provides certain advantages
when used as part of a long-term rodent
bioassay. It is the dose most likely to
induce tumors, thereby both increasing the
power ofthe study to detect carcinogenici-
ty and providing information on the types
and locations of tumors caused by the test
agent. The MTD also provides a consistent
basis for comparison across species, strains,
and sexes ofanimals (15). Rodent bioassays
also appear to be fairly sensitive at detect-
ing human carcinogens. When proven
human carcinogens are also adequately test-
ed via rodent bioassays, the bioassay results
are generally positive (19-21).
A major limitation of rodent bioassays
is that while their sensitivity appears high,
their specificity (the ability to accurately
detect noncarcinogens) is suspect. When
probable human noncarcinogens are evalu-
ated, many are still found to be positive via
rodent bioassays (19). Ames and Gold
(22,23) point out that approximately 50%
of the more than 400 chemicals that have
been adequately tested using rodent bioas-
says have been identified as carcinogens;
this is true for man-made and natural
chemicals alike. Other investigators suggest
that the percentage ofrodent carcinogens is
even higher (65%) (24). However, only a
very small fraction (0.1%) of the 60,000
commonly used chemicals have demon-
strated definite evidence of carcinogenicity
in people (21,24,25). Of course, only a
small sample of chemicals, biased toward
strong carcinogens with fairly measurable
exposure patterns, have been adequately
evaluated in people. Even so, this discrep-
ancy has led many to wonder ifsometimes
it is the methodology, not the chemical,
that is carcinogenic (17,22-24,26-28).
Many researchers have raised concerns
about the utility oflaboratory animal assays
that use doses at or near the MTD
(20,22-23,28-32). Potency estimates for
typical environmental exposure levels are
based on extrapolations from these data,
even though these high doses are very dif-
ferent from the low exposure levels found
in most domestic situations. These extrapo-
lations are dependent upon the model used
and are rarelyvalidated.
High doses ofchemicals may alter bio-
logic homeostasis, predisposing an animal
to cancer. There are several means by
which this may occur. Toxic or near-toxic
doses damage tissues, causing mitogenesis
as new cells proliferate to replace the dam-
aged ones. Mitogenesis may be a dominant
factor in chemical carcinogenesis at high
doses (near the MTD) because cell division
is a critical part of mutagenesis (23,28,29,
32-35). Tissue damage also results in inflam-
mation, releasing free radicals and other oxi-
dants that can damage DNA (36). These
responses are similar to those of tissue sub-
jected to chronic irritation/wounding, which
has been shown to cause tumorigenesis
(23,33,34).
The NTP definition of the MTD per-
mits awhole-animal toxic dose that results in
up to a 10% weight loss in the test animals
compared with the controls (16,14. Even if
a whole-animal toxic reaction is not
observed, as might occur at lower doses (i.e.,
one-tenth to one-halfthe MTD), specific tis-
sues may receive a toxic dose (18).
Furthermore, the NTP definition is difficult
to interpret (17,18), and it has been said
that, in practice, "some toxic effects may be
inevitable" from the MTD (22).
The ultimate goal ofrodent bioassays is
to make determinations about human car-
cinogenicity, which requires extrapolating
from rats and mice to people. For some
exposures, this extrapolation appears to be
reasonable. Animal-based cancer potency
estimates for asbestos, benzene, and ethyl-
ene oxide have been shown to be well with-
in the range of human-based estimates
(32). However, in many cases, the bioassay
results fail to show good agreement even
between rodent species. Research has
shown that rat and mouse studies identify
the same chemical carcinogens only about
50-75% ofthe time. This is relatively poor
agreement, considering both the physical
similarity of rats to mice (as compared to
humans) and the fact that about 50% ofall
tested chemicals are rodent carcinogens,
making chance agreement more likely
(20,38,39). Furthermore, rat and mouse
studies agree only about 35-50% of the
time regarding carcinogenicity at specific
target organs (38-40). In general, this rela-
tive lack of agreement between relatively
similar rodent species bodes poorly for the
probability of agreement between rodents
and people (38,39,41-43). In fact, one
study showed differences between risks pre-
dicted by rodent bioassays and those
demonstrated by human epidemiologic
data that ranged over 10 orders of magni-
tude (39,44).
There are also many physical, metabol-
ic, and physiological differences between
rodents and people, especially regarding
respiratory anatomy and physiology
(45-42). Laboratory rodents, unlike peo-
ple, generally have poorly defined or absent
respiratory bronchioles. Also, because of
their small body size, rodents have a much
larger relative lung volume. Furthermore,
people have quite different particle clear-
ance patterns than do laboratory rodents
(45,46). The canine respiratory system is
far more similar to that of man, although
dogs are more expensive and difficult to
manage in a laboratory setting.
It is difficult to expose laboratory ani-
mals to respiratory carcinogens in a manner
that replicates human exposure patterns.
For example, researchers investigating the
carcinogenicity oftobacco smoke frequent-
ly exposed dogs to high levels ofsmoke for
1-2 daily smoking episodes (48-51). This
pattern is not consistent with the exposures
experienced by people who smoke or are
exposed to ETS.
Exposing animals to short-term, high-
level inhalation exposures in the laboratory
has also caused respiratory illnesses and
increased mortality that limit the usefulness
ofthe results. Hernandez et al. (48) lost sev-
eral dogs to asphyxiation and noted that fre-
quent near asphyxiation probably accounted
for many of the histopathologic changes
seen. In another study, 5 of 10 dogs died
after only about 1 year of smoke exposure
(49). Hammond et al. (51) found that
approximately one-third of their smoking
dogs died from lung and/or heart problems
within 2.5 years. Similar life-span shortening
has limited the power of radon laboratory
studies to detectlung tumors in dogs (52).
The animal illness and life-span short-
ening described above highlight a further
problem of laboratory animal studies,
which has become more of an issue in
recent years-the ethics of subjecting test
animals to noxious exposures. Radon and
tobacco-smoke studies provide numerous
instances of suffering among test animals.
Rockey and Speer (49) noted that dogs are
generally not found to be willing smokers
and usually resist forced smoking. Early
smoking episodes were usually marked by
breath-holding, vomiting, conjunctivitis,
and hypersalivation. Numerous respiratory
problems, including respiratory infections,
bronchitis, emphysema, and increased
mortality, have also been noted by investi-
gators (49-52). These and other instances
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of animal suffering have prompted some
authors to suggest alternatives to traditional
laboratory animal studies (53,54).
Limitations of Traditional
Epidemiology
Unlike rodent bioassays, which use a ran-
domized experimental design that limits the
potential for bias, all epidemiology studies
have an inherent potential for bias because
of their observational nature. The various
types ofbias have been discussed in detail in
numerous epidemiology texts and review
articles (55-61). All ofthese biases fall into
three major classes: selection bias, informa-
tion bias, and confounding.
Selection bias relates to "systematic dif-
ferences in characteristics between those
who are selected for study and those who
are not" (62). This is always a potential
problem in epidemiologic studies because
subjects are not randomly allocated to
either index (exposed/case) or referent
(unexposed/control) groups, as they are in
clinical trials.
Information bias refers to errors in classi-
fyingsubjects as to either exposure ordisease.
This bias can be differential ifmisdassifica-
tion on exposure depends on disease status
(or vice versa), or nondifferential ifmisdassi-
fication on exposure is independent ofdis-
ease status (or vice versa). Differential mis-
classification can cause spurious results that
are either more extreme than reality or
toward the no-effect (null) level, depending
on the nature of the bias. Nondifferential
misdassification is usually considered to pre-
dictablybias results toward the null.
Confounding can also cause spurious
results in either direction, more extreme or
toward the null. This bias can be thought of
as guilt (or innocence) by association. It
results from the action of a variable (con-
founder) that is both a predictor ofdisease
(risk/preventive factor) and associated with
exposure. Fortunately, if this confounding
variable is identified and adequately mea-
sured, confounding can be removed during
analysis. Unfortunately, given the multitude
ofpossible confounders, this can be difficult
inpractice.
Epidemiology texts generally contain
guidelines on how to limit these biases
(55,59). Some investigators from the clini-
cal arena have also published papers sug-
gesting remedies for certain of these biases
(63,64). However, most epidemiologists
acknowledge that it is difficult, if not
impossible, to remove all threat ofbias from
an observational study (65). Subsequently,
it can be assumed that all epidemiology
studies contain some uncontrolled bias.
Biasesprevaknt in studies ofradon and
ETS. Studies of radon and ETS highlight
two biases that are a problem in all epi-
demiology studies and that are ofparticular
concern when investigating the effect of
these indoor exposures: misclassification
and confounding. Misclassification is a
problem because it is difficult to piece
together a complete exposure history for an
individual over a lifetime of 70 years or
more. Confounding is a concern because
many occupational and behavioral expo-
sures are risk factors for cancer in general
(and respiratory cancer in particular).
Misclassification. It is very difficult and
expensive to develop a full exposure history
for radon case-control studies because a per-
son maylive in manydifferent homes during
his or her lifetime. In fact, less than half of
the radon case-control studies listed as ongo-
ing in 1992 induded information on radon
levels in previous residences (66). Ofthese, a
recent Canadian study made a good effort to
identify and test all past homes, although the
investigators were able to get measurements
for only about 67% of the homes occupied
during the critical exposure period 5-30
years before the diagnosis. On average, each
participant in this study had occupied nine
different residences duringhis or her lifetime
(67). The long time periods involved also
make it difficult for subjects to recall the
duration ofresidence at each home, the time
spent away from home (at work, etc.), and
subsequent renovation and/or radon mitiga-
tion that may have changed radon levels at a
previous residence (68,69).
Assessing lifetime exposure to ETS is
similarly fraught with problems, with the
long time periods involved making recall
difficult. Many studies have used marriage
to a smoker as a measure of exposure to
ETS (7,70-74); however, individuals may
actually be exposed to three to four times
more ETS at the workplace (75). People
are also exposed to ETS in restaurants,
while socializing or traveling, and in many
other places. The extent of this exposure
may be significant, but it is difficult for
subjects to recall adequately (10,75).
Furthermore, estimates that only include
adult exposure ignore exposure from
parental smoking during childhood. Some
studies have suggested that childhood
exposure may be important at certain can-
cer sites or for certain subpopulations
(71,72,76).
Confounding. Confounding is also a
problem when trying to determine the can-
cer risk from low-level domestic exposures,
such as radon and ETS. Cancer can have
multiple etiologies, making it difficult to
gauge the independent effects of ETS and
radon. Lifestyle and dietary factors are esti-
mated to account for the largest proportion
of human cancers (77). People engage in
risky behaviors such as active cigarette
smoking, which has been estimated to
account for approximately one-third of all
human cancer and is the leading cause of
lung cancer in the United States (77).
People may also be exposed to carcinogens
in the workplace. It has been estimated that
approximately 4% ofall cancers are occupa-
tionally induced (77), although some inves-
tigators believe that this figure is much
higher (78). Occupational exposures to
radon, chromium, nickel, arsenic, asbestos,
bis(chloromethyl)ether, wood dust, soots
and tars, and several other chemicals/agents
are considered proven causes ofhuman res-
piratory cancer (25,79,80). Confounding
variables may mask the true association
between ETS, radon, and cancer.
Confounding can be controlled when it
can be adequately measured. However, the
long time periods involved and the sparsity
ofexposure records make it difficult to ade-
quately measure potentially important con-
founding factors. The resulting misclassifica-
tion ofconfounders can be even more prob-
lematic than misclassification ofexposure. It
can usually be assumed that misclassification
ofexposure is nondifferential, resulting in a
predictable error toward the null and only a
loss ofpower. However, misclassification of
confounding variables results in residual
(uncontrolled) confounding, which can
cause a spurious result that is more extreme
than expected. For example, some people
who classify themselves as nonsmokers may
actually be past or low-level smokers. These
misclassified people are at somewhat
increased cancer risk (from smoking) and
are also more likely to marry/associate with
other smokers. Therefore, this misclassifica-
tion introduces confounding into ETS/can-
cer studies, resulting in a cancer risk that is
overestimated (71).
Pet Epidemiology
History ofpetepidemiology. Domestic ani-
mals have functioned as natural sentinels of
environmental health hazards since at least
the middle ages, when the effects ofergot-
contaminated grain were recognized in
livestock (81). Recognition of the health
effects to people of toxic releases has fre-
quently been preceded by epidemics ofdis-
ease in domestic animals. For example, the
death of cattle at a livestock show in
England in 1873 was associated with a
dense industrial fog (81). This occurred
well before the human health effects of air
pollution were routinely recognized. More
recently, polychlorinated biphenyl-contam-
inated rice oil caused the death of over
400,000 chickens in Japan 6 months
before the Yusho rice oil incident that
affected over 1,000 people in that same
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Table 1. Key studiesthat utilized pet-animal epidemiologyto investigate the environmental causes of cancer
StudyType
Prevalence
comparison
Prevalence
comparison
Crude CC
Mortality
correlation
Crude CC
CC
CC
Prevalence
comparison
CC
CC
CC
Exposure
Rural vs. urban
Rural vs. urban
Rural vs. Urban
Level of local
industry
Number of
asbestos bodies
Asbestos
occupation or hobby
Topical
insecticide
Vietnam service
Herbicide use
Passive smoke
Electromagnetic fields
Associationa
8.8b
(1.9-40.6)
7.4b
(3.2-17.6)
3.3b
(1.5-7.5)
r= 0.59
(p = 0.03)
t=4.08b
(p<0.01)
8.0
(1.4-10.6)
4.2
(1.4-12.1)
2.0
(1.2-3.5)
1.3
(1.0-1.7)
1.6
(0.7-3.7)
6.8
1.6-28.5)
Disease
Tonsilar carcinoma
Pulmonary changes
Tonsilar carcinoma
Bladder cancer
Mesothelioma
Mesothelioma
Bladder cancer
Seminoma
Lymphoma
Lung cancer
Lymphoma
Reference
(83)
(84)
CC, case-control; OR, odds ratio.
alUnless otherwise indicated,the measure of association is the OR. The numbers in parentheses are 95%
confidence intervals or p-values.
'These ORs/tests were not included inthe original publications and have been calculated by one ofthe
authors (JAB).
country (81). Similarly, the environmental
health effects of aflatoxin, chlorinated
naphthalene, dioxin, DDE, leptophos,
organic mercury, and other chemicals were
first identified in domestic animals (81,82).
These early animal-sentinel examples
dealt primarily with acute intoxications
among farm animals. Pets are better suited
as sentinels ofchronic exposure to residen-
tial carcinogens because of the intimate
association between pets and the domestic
environment of people. However, studies
of residential exposures in pets are limited
to a relatively few investigations that have
been conducted over the last 20-30 years.
Most of these have investigated potential
domestic carcinogens (Table 1) (83-93).
In 1967, Ragland and Gorham (83)
noted an eight times greater prevalence of
tonsillar carcinoma among dogs from an
urban area (Philadelphia, PA) compared
with dogs from rural Washington State.
This urban/rural difference in the preva-
lence of tonsillar carcinoma was later con-
firmed by Reif and Cohen (85). Reif and
Cohen (84) also noted that there was a
greater prevalence of chronic pulmonary
changes in the lungs ofolder dogs that had
lived in urban areas. Similarly, a study per-
formed by Hayes et al. (86) showed asignif-
icant positive correlation between the pro-
portional mortality ratio (PMR) for canine
bladder cancer and level ofindustrial activi-
ty in the host county ofthe animal hospital.
The early observational studies cited
above were somewhat crude in design and
suffered from significant deficiencies. Two of
these studies were primarily correlational,
with limited data regarding exposure or dis-
ease among individual dogs (83,86). None of
the investigators contacted the dog owners to
obtain information on exposures orpotential-
lyimportant confoundingvariables. Exposure
measurements were limited to crude esti-
mates of regional industrialization or urban-
ization, creating the potential for significant
misclassification (83-86). Potential con-
founders were limited to age, breed, and sex,
although only two ofthe studies adjusted for
these variables in the analysis (84,86).
Furthermore, allofthe investigatorswerelim-
ited analytically because ofthe lack ofmod-
erncomputerized statistical methods.
During the last two or three decades,
refinements to the case-control approach
have made this a key epidemiologic tool
(57,94), and more recent pet cancer epi-
demiology studies have used the case-control
approach. A case-control studyby Glickman
et al. (88) demonstrated a significant positive
association between canine mesothelioma
and an asbestos-related occupation or hobby
in ahousehold member. These findings were
supported by those of Harbison and
Godleski (8/), who found significantly more
asbestos bodies (asbestos fibers coated with
an iron protein complex) among dogs with
mesothelioma than among control dogs.
These two studies confirmed this common
cause for human and canine mesothelioma.
They also showed the utility ofdogs as mark-
ers ofasbestos exposure, an idea suggested in
1931 by the diagnosis ofasbestosis in a dog
that lived in anasbestos factory (95).
Several other case-control studies on
cancer in pets have been reported. Glickman
et al. (89) demonstrated an association
between topical insecticide use and canine
bladder cancer. Hayes et al. (91) showed a
small but significant association [odds ratio
(OR) = 1.3] between canine malignant lym-
phoma and the application ofphenoxy her-
bicide lawn care products. Reif et al. (92)
found a weak association [OR = 1.6; 95%
confidence interval (CI), 0.7-3.7] between
ETS and canine lung cancer. However, this
study found that the increased risk was
restricted to dogs with short- or medium-
length noses, suggesting that nasal cancer
may be a better endpoint for this exposure
than lung cancer (92). Most recently, Reifet
al. (93) demonstrated an increased risk for
lymphoma among dogs exposed to electro-
magnetic fields around the home.
These case-control studies were meth-
odologically superior to the earlier studies
reported. Most of the investigators gath-
ered information on exposure and con-
founding variables directly from the owners
(88,89,91-93). Also, the availability of
computers, as well as the statistical
advances associated with them, allowed for
improved analyses. Confounding variables
were controlled either through stratifica-
tion (88,92) or through logistic regression
modeling (89,91,93).
Advantages. Usually, no single study
can be used to make the determination that
an individual environmental agent causes a
particular cancer. Instead, a weight-of-evi-
dence approach is used. In general, well-
designed pet epidemiology studies can add
significantly to the weight ofevidence con-
cerning the environmental causes ofcancer
in both animals and people. This approach
forms an attractive addition to traditional
laboratory animal and human observational
investigations.
When evaluating causality using a
weight-of-evidence approach, similar find-
ings across varied studies is one of the key
criteria to consider (59). For example, a pos-
itiveepidemiologicassociation is morecredi-
ble if it supports the findings of other epi-
demiologic studies or oflaboratory animal
studies. Apositive result from apetepidemi-
ology studywould further enhance the cred-
ibility of the association. Pet epidemiology
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studies could also act as a tie-breaker when
the results from traditional approaches are
at odds.
The approximately 50 million pet dogs
currently in the United States represent a
relatively untapped source ofinformation on
disease causation. Many ofthese dogs come
from genetically distinct breeds with varying
risks for particular cancers, facilitating the
differentiation of genetic influences from
environmental ones (54). Furthermore, the
owners ofthese dogs are often very coopera-
tive, and participation rates for pet epidemi-
ology studies are high. For their study inves-
tigating the association between canine
malignant lymphoma and herbicide expo-
sure, Hayes et al. (91) noted that ofthe over
1,400 case and control owners contacted,
only four refused to participate.
In many respects, pet dogs form an
excellent surrogate population for exploring
the carcinogenic potential of the domestic
environment in which people live. Pet dogs
live in close association with people and
share domestic exposures with them; how-
ever, dogs do not directly engage in the
high-risk behaviors and occupations experi-
enced by their human masters. Also, dogs
have shorter life spans and cancer latency
periods than do people, allowing them to
be used as early sentinels of environmental
problems. Furthermore, only fairly recent
environmental exposures need to be mea-
sured, enhancing the quality of recalled
information and minimizing both exposure
misclassification and recall bias (54).
Differential recall would still be possible,
but it is likely that people would not experi-
ence the same recall stimulus from cancer in
a pet as they would from their own cancer
or that ofa close family member.
Active smoking and occupation are the
major confounders that plague traditional
environmental epidemiology studies. Pets
are free of these exposures, although low-
level exposure to workplace carcinogens may
still occur from materials (e.g., lead and
asbestos) that adhere to clothing worn in the
workplace. The relatively short recall period
in pet studies would enhance the measure-
ment of other less critical confounding fac-
tors (such as diet and socioeconomic status),
thereby limiting residual confounding from
incomplete control ofthese factors.
Dogs have also been shown to be good
models for many human cancers. Several
investigators have demonstrated that canine
and human mammary cancer share impor-
tant clinical and histological features
(96-99). Other authors have shown similar-
ities between human and canine bone can-
cer (100,101), bladder cancer (86,97,102),
and nasal cancer (103). Dogs have been
shown to be especially good models for
human respiratory cancer and have been
used in laboratory studies to investigate the
health effects of exposure to both tobacco
smoke and radon. Cigarette smoke has been
shown to cause similar histologic changes to
the lungs of both people and beagle dogs
(50,51). Radon has been shown to cause
lung cancer in laboratory dogs at levels that
did not greatly exceed exposures reported
for uranium miners (52). Dogs are also sim-
ilar to humans in that their incidence ofres-
piratory tract tumors is linearly related to
both increasing cumulative radon exposure
and unattached fraction (52). In general,
the dog is the best model for inhalation
studies in which comparisons to humans
are to be made (45).
Pets are not only good markers ofeffect;
they have also proven to be useful markers
ofexposure. Thomas et al. (104) found that
pet dogs with high blood lead levels could
be used to predict higher blood lead levels in
children from the same family. Kucera (105)
found a positive correlation between blood
lead levels in pet dogs and the density of
nearby local traffic patterns, highlighting the
historical importance ofthis route ofhuman
exposure. More recently, Reynolds et al.
(106) found significantly higher urinary lev-
els of the herbicide 2,4-dichlorophenoxy-
acetic acid (2,4-D) among dogs from treated
homes compared to those from nontreated
ones. However, differences in absorption,
metabolism, and excretion between dogs
and people must always be considered when
using pet dogs as exposure sentinels. For
example, Reynolds et al. (106) found elevat-
ed 2,4-D levels in canine urine samples even
more than 2 weeks following exposure.
People excrete 2,4-D much more rapidly,
eliminating almost the entire absorbed dose
in approximately 4 days (107). Relying sole-
ly on canine exposure models would greatly
overestimate 2,4-D bodyburdens inpeople.
Observational studies of pet popula-
tions also represent a humane alternative to
laboratory animal experimentation (54).
Unlike laboratory animal studies, the cases
in pet cancer studies are not subject to nox-
ious or debilitating exposures by investiga-
tors. Well-designed pet epidemiology stud-
ies can provide an additional independent
approach to cancer research, thereby reduc-
ing the number oflaboratory animal stud-
ies needed to build a body of evidence for
carcinogenicity.
Limitations ofpet epidemiology. Pet
epidemiology studies are observational in
nature and therefore share many of the
biases inherent in human epidemiology.
Exposures are still usually estimated from
retrospective interviews, setting up the pos-
sibility of misclassification and recall bias.
Similarly, selection bias and confounding
are potential problems. However, as men-
tioned previously, the magnitude of these
biases should be greatly lessened in pet
studies. Also, the same techniques used to
limit these biases in human epidemiology
studies (e.g., cancer controls to limit differ-
ential recall, stratified or multivariate analy-
ses to control confounding, etc.) can be
applied to pet studies as well.
An important limitation of pet epi-
demiology is a lack ofessential population
and disease data. Only a handful of U.S.
animal disease registries have ever existed
(108-110). Monsein (110) suggests that
these suffer from inaccuracies, biases, and
an inability to provide reliable incidence or
mortality rates, which limits their utility for
analytical epidemiology studies. Use of the
case-control approach has overcome much
ofthe need for population rates but not the
paucity of available disease data. Most of
the case-control studies on cancer in pets
have contained fewer than 100 cases. Only
the malignant lymphoma study reported by
Hayes et al. (91) had sufficient power to
detect relatively small associations. This
study contained almost 500 cases and more
than 900 tumor and nontumor controls.
This paucity of accurate disease infor-
mation is (in large part) driven by economic
considerations. Although veterinary care has
an absolute cost that is much less than simi-
lar human medical care, the lack of third-
party reimbursement makes veterinary care
relatively more expensive and unaffordable
to many dog owners (54). When faced with
a severe chronic disease such as cancer,
many owners opt for euthanasia rather than
pursuing expensive diagnostics and treat-
ment. These cases are never presented to a
veterinary teaching hospital where they
might become part of a diagnostic or
histopathology database. Because there are
also no mandated death or cancer registries
for dogs, only a small fraction of cancer
cases could be expected to come to the
attention ofveterinary epidemiologists.
An additional economic consideration
that hampers pet cancer epidemiology is the
lack ofavailable funding. Agencies that tradi-
tionally support similar human cancer epi-
demiology may not appreciate the potential
benefits of a pet approach. Glickman and
Domanski (54) cite an example of a study
investigating diet and canine breast cancer,
which was submitted to a major federal fund-
ing agency. The reviewers acknowledged the
similarities between canine and human breast
cancerand the relevance ofthe research. They
also noted that this researchwould address an
important issue that is difficult to assess by
observational research in women. However,
they gave the study a low priority because
"For all its virtues, however, this is a study of
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dogs and can never achieve the priority of a
comparablydesigned studyin humans" (54).
The above opinion reflects a lack of
comfort with the pet approach, which may
be shared by many researchers. The herbi-
cide/canine malignant lymphoma study by
Hayes et al. (91) was harshly criticized for
relying on questionnaire responses and not
ascertaining actual herbicide body burdens
(111,112). However, a similar level ofcriti-
cism was not leveled at the large number of
human epidemiology studies that have
relied on questionnaire responses, nor did
the critics consider the advantages of the
shorter recall period possible in this pet epi-
demiology study. These critics were appar-
ently unable to separate the novelty of the
approach from its strengths and weaknesses.
Conclusion
For many reasons, pet cancer studies form a
valuable complement to laboratory animal
and human epidemiology studies. Pets live
in intimate association with the local
domestic environment ofpeople and repre-
sent good models for many types ofhuman
cancers. These studies usually obtain good
compliance from pet owners, who are often
excited about the possibility that the cancer
in their pet could help further the war
against cancer. Also, the information that
these owners supply may be ofbetter quali-
ty than that obtained in similar human ret-
rospective studies because pet owners only
need to recall a relatively short time span of
5-15 years. Finally, pet cancer studies never
subject animals to noxious exposures, there-
by representing an attractive alternative to
laboratory animal approaches.
Certainly, pet research cannot totally
replace the more traditional research tech-
niques; however, pet studies represent a
unique line of inquiry that explores cancer
causality from an independent direction.
This makes pet studies ideally suited to the
weight-of-evidence approach that is cur-
rently used to define the carcinogenic
potential ofenvironmental exposures.
REFERENCES
1. National Research Council. Indoor Pollutants.
Committee on Indoor Pollutants, Board on
Toxicology and Environmental Health
Hazards, Assembly of Life Sciences, National
Research Council. Washington, DC:National
Academy Press, 1981.
2. Lewtas J. Airborne carcinogens. Pharmacol
Toxicol 72 (S1):55-63 (1993).
3. Wallace LA, Pellizzari ED. Personal air expo-
sures and breath concentrations ofbenzene and
other volatile hydrocarbons for smokers and
nonsmokers. Toxicol Lett 35:113-116 (1986).
4. Samet JM. Radon and lung cancer. J Natl
Cancer Inst 81(10):745-757 (1989).
5. Bierma TJ. Radon risk factors: evaluating the
health implications of home exposures. J
Environ Health 51(5):277-281 (1989).
6. Nero AV. Estimated risk of lung cancer from
exposure to radon decay products in U.S.
homes: a brief review. Atmos Environ 22(10):
x2205-2211 (1988).
7. Humble CG, Samet JM, Pathak DR. Marriage
to a smoker and lung cancer risk. Am J Public
Health 77(5):598-602 (1987).
8. Eriksen MP, LeMaistre CA, Newell GR.
Health hazards of passive smoking. Annu Rev
Public Health 9:47-70 (1988).
9. Saracci R, Riboli E. Passive smoking and lung
cancer: current evidence and ongoing studies at
the International Agency for Research on
Cancer. Mutat Res 222:117-127 (1989).
10. Wu-Williams AH, Samet JM. Environmental
tobacco smoke: exposure-response relationships
in epidemiologic studies. RiskAnal 10(1):39-48
(1990).
11. Chesebro MJ. Passive smoking. Am Fam
Physican 37(5):212-218 (1988)
12. Friedman GD, Petitti DB, Bawol RD. Prev-
alence and correlates ofpassive smoking. Am J
Public Health 73(4):401-405 (1983).
13. Vainio H, Partanen T. Population burden of
lung cancer due to environmental tobacco
smoke. Mutat Res 222:137-140 (1989).
14. Paxman DG, Robinson JC. Regulation of
occupational carcinogens under OSHA's air
contaminants standard. Regul Toxicol
Pharmacol 12:296-308 (1990).
15. National Research Council. Issues in risk
assessment: use ofthe maximum tolerated dose
in animal bioassays for carcinogenicity.
Washington, DC:NationalAcademyPress, 1993.
16. McConnell EE. The maximum tolerated dose:
the debate. J Am College Toxicol 8(6):
1115-1120 (1989).
17. Clayson DB, Iverson F, Mueller R. An applica-
tion ofthe maximum tolerated dose: an inade-
quately precise decision point in designing a
carcinogenesis bioassay? Teratogen Carcinogen
Mutagen 11:279-296 (1991).
18. Clayson DB, Clegg DJ. Classification of car-
cinogens: polemics, pedantics, or progress.
Regul Toxicol Pharmacol 14:147-166 (1991).
19. Ennever FK, Noonan TJ, Rosenkranz HS. The
predictivity of animal bioassays and short-term
genotoxicity tests for carcinogenicity and non-
carcinogenicity to humans. Mutagenesis 2:73-78
(1987).
20. Gregory AR. Species comparisons in evaluating
carcinogenicity in humans. Regul Toxicol
Pharmacol 8:160-190 (1988).
21. Munro A. How useful are chronic (life-span) tox-
icology studies in rodents in identifying pharma-
ceuticals that pose a carcinogenic risk to humans?
Adverse Drug React Toxicol Rev 12(1):5-34
(1993).
22. Ames BN, Gold LS. Too many rodent carcino-
gens: mitogenesis increases mutagenesis. Science
249:970-971 (1990).
23. Ames BN, Gold LS. Animal cancer tests and can-
cer prevention. J Nail Cancer Inst Monogr 12:
125-132 (1992).
24. Lave LB, Ennever FK, Rosenkranz HS,
Omenn GS. Information value of the rodent
bioassay. Nature 336:631-633 (1988).
25. Tomatis L, Aitio A, Wilbourn J, Shuker L.
Human carcinogens so far identified. Jpn J
Cancer Res 80:795-807 (1989).
26. Abelson PH. Testing for carcinogens with
rodents [editorial]. Science 249:1357 (1990).
27. Goodman G, Wilson R. Predicting the car-
cinogenicity of chemicals in humans from
rodent bioassay data. Environ Health Perspect
94:195-218 (1991).
28. Ashby J, Morrod RS. Detection ofhuman car-
cinogens. Nature 352:185-186 (1991).
29. Cohen SM, Ellwein LB. Cell proliferation and
carcinogenesis. Science 249:1007-1011 (1990).
30. Trosko JE. Towards understanding carcino-
genic hazards: a crisis in paradigms. J Am Coll
Toxicol 8(6):1121-1132 (1989).
31. Clayson DB. Can amechanistic rationale be pro-
vided for non-genotoxic carcinogens identified in
rodent bioassays? Mutat Res 221:53-67 (1989).
32. Butterworth BE. Consideration of both geno-
toxic and nongenotoxic mechanisms in pre-
dicting carcinogenic potential. Mutat Res
239:117-132 (1990).
33. Clayson DB. Bladder carcinogenesis in rats and
mice: possibility ofartifacts. J Natl Cancer Inst
52(6):1685-1689 (1974).
34. Preston-Martin S, Pike MC, Ross RK, Jones PA,
Henderson BE. Increased cell division as a cause
of human cancer. Cancer Res 50:7415-7421
(1990).
35. Preston-Martin S, Pike MC, Ross RK,
Henderson BE. Epidemiologic evidence for the
increased cell proliferation model ofcarcinogen-
esis. In: Chemically Induced Cell Proliferation:
Implications for Risk Assessment (Butterworth
BE, Slaga TJ, Farland W, McClain M, eds).
NewYork:Wiley-Liss, 1991;21-34.
36. Imlay JA, Linn S. DNA damage and oxygen
radical toxicity. Science 240:1302-1309
(1988).
37. Hertz-Picciotto I, Gravitz N, Neutra R. How
do cancer risks predicted from animal bioassays
compare with the epidemiologic evidence? The
case of ethylene dibromide. Risk Anal
8(2):205-214 (1988).
38. Gold LS, Manley NB, Ames BN. Extrapolation
of carcinogenicity between species: qualitative
and quantitative factors. Risk Anal 12(4):
579-588 (1992).
39. Wartenberg D, Simon R Comment: Integrating
epidemiologic data into risk assessment. Am J
Public Health 85(4):491-493 (1995).
40. Haseman JK, Lockhart AM. Correlations
between chemically related site-specific carcino-
geniceffects in long-term studies in rats and mice.
Environ Health Perspect 101:50-54 (1993).
41. Allen B, Crump K, Shipp A. Correlation
between carcinogenic potency of chemicals in
animals and humans. Risk Anal 8:531-544
(1988).
42. Shore R, Iyer V, Altshuler B, Pasternack B. Use
of human data in quantitative risk assessment
of carcinogens: impact on epidemiologic prac-
tice and the regulatory process. Regul Toxicol
Pharmacol 15:180-221 (1992).
43. Berry CL. Pesticides. Hum Toxicol 7:433-436
(1988).
44. Portier C. Species correlation of chemical car-
cinogens. RiskAnal 8:551-553 (1988).
45. Reznik-Schuller H, Reznik G. Experimental
pulmonary carcinogenesis. Int Rev Exp Pathol
20:211-281 (1979).
46. Warheit DB. Interspecies comparisons oflung
responses to inhaled particles and gases. CRC
Crit Rev Toxicol 20(1):1-29 (1989).
47. Lippmann M, Schlesinger RB. Interspecies
comparisons ofparticle deposition and mucocil-
iary clearance in tracheobronchial airways. J
Toxicol Environ Health 13(1):441-469 (1984).
Environmental Health Perspectives * Volume 105, Number 12, December 1997 1317Review - Bukowski and Wartenberg
48. Hernandez JA, Anderson AE Jr, Holmes WL,
ForakerAG. Pulmonary parenchymal defects in
dogs following prolonged cigarette smoke expo-
sure. Am Rev Respir Dis 93(1):78-83 (1966).
49. Rockey EE, Speer FD. The ill effects of ciga-
rette smoking in dogs. Int Surg 46(6):520-530
(1966).
50. Zwicker FM, Filipy RE, ParkJF, LoscutoffSM,
Ragan HA, Stevens DL Clinical andpathological
effects ofcigrettesmokeeqxosure in beagledogs.
Arch Pathol LabMed 102:623-628 (1978).
51. Hammond EC, Auerbach 0, Kirman D,
Garfinkel L. Effects of cigarette smoking on
dogs: I. Design of experiment, mortality, and
findings in lung parenchyma. Arch Environ
Health 21:740-753 (1970).
52. Cross FT, Palmer RF, Filipy RE, Dagle DE,
Stuart BO. Carcinogenic effect ofradon daugh-
ters, uranium ore dust and cigarette smoke in
beagle dogs. Health Phys 42(1):33-52 (1982).
53. Will JA. An overview ofalternatives. Lab Anim
14:37-41 (1985).
54. Glickman LT, Domanski LM. An alternative to
laboratory animal experimentation for human
health risk assessment: epidemiological studies
of pet animals. Altern Lab Anim 13:267-285
(1986).
55. Mausner JS, Kramer S. Mausner & Bahn
Epidemiology: An Introductory Text. Phila-
delphia, PAWB Saunders Co., 1985.
56. Kleinbaum DG, Kupper LL, Morgenstern H.
Epidemiologic Research: Principles and
Quantitative Methods. NewYork.Van Nostrand
Reinhold, 1982.
57. Schlesselman JJ. Case-Control Studies. New
York.Oxford University Press, 1982.
58. Hennekens CH, Buring JE. Epidemiology in
Medicine. Boston, MA.Little, Brown, and Co.,
1987.
59. Rothman KJ. Modern Epidemiology. Boston,
MA.Little, Brown and Co., 1986.
60. KelseyJL, Thompson WD, Evans AS. Methods
in Observational Epidemiology. New York:
Oxford University Press, 1986.
61. Austin H, Hill HA, FlandersWD, GreenbergRS.
Limitations in the application ofcase-control
methodology.Epidemiol Rev 16(1):65-76 (1994).
62. Last JM, ed. A Dictionary of Epidemiology.
NewYork.Oxford University Press, 1983.
63. Feinstein AR, Horwitz RI. Double standards,
scientific methods, and epidemiologic research.
N EnglJ Med 307(26):1611-1617 (1982).
64. Gray-Donald K, Kramer MS. Causalityinference
in observational vs. experimental studies. An
empirical comparison. Am J Epidemiol 127(5):
885-892 (1988).
65. Taubes G. Epidemiology faces its limits. Science
269:164-169 (1995).
66. Neuberger JS. Residential radon exposure and
lung cancer: an overview of ongoing studies.
Health Phys 63(5):503-509 (1992).
67. LetourmeauEG, Krwski D, ChoiNW, Goddard
MJ, McGregor RG, Zielinski JM, Du J.
Case-control study ofresidential radon and lung
cancer in VWmnipeg, Manitoba, Canada. Am J
Epidemiol 140:310-322(1994).
68. Lubin JH, Samet JM, Weinberg C. Design
issues ofepidemiologic studies ofindoor expo-
sure to Rn and riskoflung cancer. Health Phys
99(6):807-817 (1990).
69. Samet JM, Stolwijk J, Rose SL. Summary:
Intemational Workshop on Residential Radon
Epidemiology. Health Phys 60(2):223-227
(1991).
70. Dalager NA, Pickle LW, Mason TJ, Correa P,
Fontham E, Stemhagen A, Buffler PA, Ziegler
RG, FraumeniJF. The relation ofpassive smok-
ing to lung cancer. Cancer Res 46:4808-4811
(1986).
71. Woodward A, McMichael AJ. Passive smoking
and cancer risk: the nature and uses of epi-
demiological evidence. Eur J Cancer 27(11):
1472-1479 (1991).
72. Stockwell HG, Goldman AL, Lyman GH,
Noss CI, Armstrong AW, Pinkham PA,
Candelora EC, Brusa MR. Environmental
tobacco smoke and lung cancer risk in non-
smoking women. J NatI Cancer Inst 84:
1417-1422 (1992).
73. Pershagen G, Hrubec Z, Svensson, C. Passive
smoking and lung cancer in Swedish women.
AmJ Epidemiol 125(1):17-24 (1987).
74. Akiba S, Kato H, Blot WJ. Passive smoking
and lung cancer among Japanese women.
Cancer Res 46:4804-4807 (1986).
75. Muir-Gray JA, Millard DW, Walton J. Passive
smoking in the workplace nuisance or risk?
Statement of the Green-College Consensus
Conference. Community Med 9(3):209-215
(1987).
76. Kabat GC, Steilman SD, Wynder EL. Relation
between exposure to environmental tobacco
smoke and lung cancer in lifetime nonsmokers.
AmJ Epidemiol 142:141-148 (1995).
77. Doll R, Peto R The Causes ofCancer. Oxford:
Oxford University Press, 1981.
78. Landrigan PJ, Markowitz S. Current magnitude
ofoccupational disease in the United States.
Estimates from New York State. In:
Occupational Health in the 1990s: Developing a
Platform for Disease Prevention (Landrigan PJ,
SelikoffIJ, eds). New York.New York Academy
ofSciences, 1989;27-45.
79. Swanson GM. Cancer prevention in the work-
place and natural environment. Cancer 62:
1725-1746 (1988).
80. Schottenfeld D. Chronic disease in the work-
place and environment: cancer. Arch Environ
Health 39(3):150-157 (1984).
81. National Research Council.Animals asSentinels
ofEnvironmental Health Hazards. Washington,
DC:NationalAcademy Press, 1991.
82. BuckWB.Animals as monitorsofenvironmental
quality. Vet HumToxicol21:277-284 (1979).
83. Ragland WL, Gorham JR Tonsilar carcinoma
in rural dogs. Nature 214:925-926 (1967).
84. ReifJS, Cohen D. Retrospective radiographic
analysis ofpulmonary disease in rural and urban
dogs.Arch Environ Health20:684-689 (1970).
85. ReifJS, Cohen D. The environmental distribu-
tion ofcanine respiratory tract neoplasms. Arch
Environ Health 22:136-140 (1971).
86. Hayes HM Jr, Hoover R, Tarone RE. Bladder
cancer in pet dogs: asentinel for environmental
cancer? Am J Epidemiol 114(2):229-233
(1981).
87. Harbison ML, GodleskiJJ. Malignant mesothe-
lioma in urban dogs. Vet Pathol 20:531-540
(1983).
88. Glickman LT, Domanski LM, Maguire TG,
Dubielzig RR, Churg A. Mesothelioma in pet
dogs associated with exposure of their owners
to asbestos. Environ Res 32:305-313 (1983).
89. Glickman LT, Shofer FS, McKee LJ, ReifJS,
Goldschmidt MH. Epidemiologic study of
insecticide exposures, obesity, and risk ofblad-
der cancer in household dogs. J Toxicol
Environ Health 28:407-414 (1989).
90. Hayes HM, Tarone RE, Casey HW, Huxsoll
DL. Excess ofseminomas observed in Vietnam
service U.S. military working dogs. J Natl
Cancer Inst 82:1042-1046 (1990).
91. Hayes HM, Tarone RE, Cantor KP,Jessen CR,
McCumin DM, Richardson RC. Case-control
study of canine malignant lymphoma: positive
association with dog owner's use of 2,4-
dichlorophenoxyacetic acid herbicides. J Natl
Cancer Inst 83:1226-1231 (1991).
92. Reif JS, Dunn K, Ogilvie GK, Harris CK.
Passive smoking and canine lung cancer risk.
AmJ Epidemiol 135(3):234-239 (1992).
93. ReifJS, LowerKS, Ogivie GK Residential expo-
sure to magnetic fields and risk of canine lym-
phoma. AmJ Epidemiol 141:352-359 (1995).
94. Cole P. The evolving case-control study. J
Chron Dis 32:15-27 (1979).
95. Schuster NH. Pulmonary asbestosis in a dog. J
Pathol Bacteriol 34:751-757 (1931).
96. Schneider R Comparison ofage, sex, and inci-
dence rates in human and canine breast cancer.
Cancer 26:419-426 (1970).
97. Hayes HM. The comparative epidemiology of
selected neoplasms between dogs, cats and
humans. A review. EurJ Cancer 00:1299-1308
(1978).
98. Shofer FS, Sonnenschein EG, Goldschmidt
MH, Laster LL, Glickman LT. Histopathology
and dietary prognostic factors for canine mam-
mary carcinoma. Breast Cancer Res Treat 13:
49-60 (1989).
99. Sonnenschein EG, Glickman LT, Goldschmidt
MH, McKee LJ. Body conformation, diet, and
breast cancer in dogs: a case-control study. Am
J Epidemiol 133:694-703 (1991).
100.Brodey RS. The use ofnaturally occurring can-
cer in domestic animals for research into
human cancer: general considerations and a
review ofcanine osteosarcoma. YaleJ Biol Med
52:345-361 (1979).
101.Tjalma RA. Canine bone sarcoma: estimation
ofrelative risk as a function ofbody size. J Nad
Cancer Inst 36:1137-1150 (1966).
102. Hayes HM. Canine bladder cancer: epidemio-
logic features. AmJ Epidemiol 104(6):673-677
(1976).
103. Hayes HM, Wllson GP. Comparative aspects of
nasal passage carcinoma in dogs with man. In:
Nasal Tumors in Animals and Man (Reznik G,
Stinson SF, eds). Boca Raton, FL:CRC Press,
1983.
104.Thomas CW, RisingJL, MooreJK Blood lead
concentrations of children and dogs from 83
Illinois families. J Am Vet Med 169(11):
1237-1240 (1976).
105. Kucera E. Dogs as indicators ofurban leaddistri-
bution. Environ MonitAssess 10:51-57 (1988).
106.Reynolds PM, ReifJS, Ramsdell HS, Tessari
JD. Canine exposure to herbicide-treated lawns
and urinary excretion of2,4-dichlorophenoxy-
acetic acid. Cancer Epidemiol Biomarkers Prev
33:233-237 (1994).
107.Lillienfeld DE, Galo MA. 2,4-D, 2,4,5-T, and
2,3,7,8-TCDD: an overview. Epidemiol Rev
11:28-58 (1989).
108. Dom CR, Taylor DON, Schneider R, Hibbard
HH, Klauber MR Survey ofanimal neoplasms
in Alameda and Contra Costa Counties,
California. II. Cancer morbidity in dogs and cats
from Alameda County. J Natl Cancer Inst
40:307-318 (1968).
109. MacVean DW, Monlux AW, Anderson PS,
Silberg SL, Roszell JF. Frequeney ofcanine and
1318 Volume 105, Number 12 December 1997 * EnvironmentalHealth PerspectivesReview * Pets as sentinels ofcancer risk
feline tumors in adefinedpopulation. Vet Pathol
15:700-715 (1978).
110.Monsein DL. An overview of animal cancer
registries in the United States and suggestions
for improved applications. Compendium on
Continuing Education for the Practicing
Veterinarian 13(7):1139-1146 (1991).
111. Sternberg SS. Canine malignant lymphoma
and 2,4-dichlorophenoxyacetic acid herbicides
[letter]. J Natl Cancer Inst 84:271 (1992).
112. Carlo GL, Cole P, Miller AB, Munro IC,
Solomon KR, Squire RA. Review of a study
reporting an association between 2,4-
dichlorophenoxyacetic acid and canine malig-
nant lymphoma report ofan expert panel. Regul
Toxicol Pharmacol 16:245-252 (1992).
29TH MEETING OF THE ENVIRONMENTAL MUTAGEN SOCIETY
MARCH 21-26, 1998
DISNEYLAND HOTEL, ANAHEIM CALIFORNIA
DEADLINES:
LATE-BREAKING ABSTRACTS: JANUARY 23, 1998
ADVANCED REGISTRATION: JANUARY 23, 1998
DISNEYLAND HOTEL REGISTRATION: FEBRUARY 20, 1998
SYMPOSIA:
DNA DAMAGE:
MITOCHONDRIAL DNA B. VAN HOUTEN
DNA REPAIR:
TRANSCRIPTION COUPLED REPAIR AND HUMAN DISEASE P. HANAWALT
INTERACTIONS OF RAD51 AND BRCA1 L. THOMPSON
MECHANISMS OF SPONTANEOUS MUTAGENESIS T. KUNKEL
GENOMICS:
ANALYSIS OF GENOMES FROM DROSOPHILA TO MAN A. CARRANO
RISK ASSESSMENT:
CASE STUDIES OF CHLOROFORM, BUTADIENE, ASBESTOS, AND V. DELLARCO AND
PHENOLPHTHALEIN D. JACOBSON-KRAM
DOSE RESPONSE AND THRESHOLDS G. KRISHNA; B. GOLLAPUDI
ENVIRONMENTAL GENOMICS:
GENE-ENVIRONMENT INTERACTIONS IN HUMAN GENETIC DISEASES R. ALBERTINI
HUMAN MONITORING AND MOLECULAR EPIDEMIOLOGY OF CANCER D. ANDERSON; C.AMBROSONE
MINI-MEETING
TRANSGENIC ANIMALS IN MUTAGENICITY/CARCINOGENICITY STUDIES B. GLICKMAN AND
N. GORELICK (1 1/2 DAYS)
WORKSHOPS, STUDENT PROGRAMS, EXCURSIONS, AND DISNEYLAND
INFORMATION: ABSTRACT FORMS/REGISTRATION:
DR. ROSALIE ELESPURU, PROGRAM CHAIR MS. MAUREEN THOMPSON
PHONE: (301) 443-0566 PHONE: (703) 437-4377
FAX: (301) 594-6775 FAX: (703) 435-4390
E-MAIL: RKE@CDRH.FDA.GOV E-MAIL: EMSDMG@AOL.COM
EnvironmentalHealth Perspectives * Volume 105, Number 12, December 1997 1319